# Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults

> **NCT00712803** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 29 (actual)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** rDEN3-3'D4delta30
- **BIOLOGICAL:** rDEN3-3'D4delta30
- **BIOLOGICAL:** rDEN3-3'D4delta30

## Key facts

- **NCT ID:** NCT00712803
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2013-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00712803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00712803, "Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00712803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*